About pfizer inc. - PFE
PFE At a Glance
| Phone | 1-212-733-2323 | Revenue | 62.58B | |
| Industry | Pharmaceuticals: Major | Net Income | 7.77B | |
| Sector | Health Technology | Employees | 75,000 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
PFE Valuation
| P/E Current | 19.883 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 18.364 |
| Price to Sales Ratio | 2.273 |
| Price to Book Ratio | 1.637 |
| Price to Cash Flow Ratio | 12.15 |
| Enterprise Value to EBITDA | 8.286 |
| Enterprise Value to Sales | 3.138 |
| Total Debt to Enterprise Value | 0.343 |
PFE Efficiency
| Revenue/Employee | 834,386.667 |
| Income Per Employee | 103,613.333 |
| Receivables Turnover | 5.27 |
| Total Asset Turnover | 0.297 |
PFE Liquidity
| Current Ratio | 1.16 |
| Quick Ratio | 0.872 |
| Cash Ratio | 0.368 |
PFE Profitability
| Gross Margin | 65.573 |
| Operating Margin | 27.335 |
| Pretax Margin | 12.017 |
| Net Margin | 12.418 |
| Return on Assets | 3.675 |
| Return on Equity | 8.869 |
| Return on Total Capital | 5.033 |
| Return on Invested Capital | 5.193 |
PFE Capital Structure
| Total Debt to Total Equity | 77.959 |
| Total Debt to Total Capital | 43.807 |
| Total Debt to Total Assets | 32.387 |
| Long-Term Debt to Equity | 73.93 |
| Long-Term Debt to Total Capital | 41.543 |
Pfizer Inc. in the News
Top 5 most expensive drugs for consumers
Five top-selling drugs, in some cases, are costing Americans thousands in out of pocket expenses weekly and monthly. Here's the list.
FDA may revoke Pfizer COVID-19 vaccine authorization for kids under certain age
The Food and Drug Administration could pull Pfizer's coronavirus vaccine emergency authorization for children under age 5.
Republicans subpoena former Pfizer exec over timing of COVID vaccine clinical tests
The House Judiciary Committee subpoenaed a former Pfizer executive who allegedly claimed senior members of the company delayed the results of COVID-19 vaccine trials to influence the 2020 election.
Pfizer will end development of daily weight-loss pill after liver injury
Pfizer is facing another setback with its weight-loss pill, danuglipron. The pharmaceutical giant stopped development of the drug after liver issues affected one patient.
Kansas sues Pfizer over 'misrepresentations' and 'adverse events' of COVID-19 vaccine
The State of Kansas has filed a lawsuit against Pfizer, Inc. for alleged consumer protection violations related to the company's manufacturing of the COVID-19 vaccine.
Left-wing activism rampant in corporate shareholder proposal process: report
A Securities and Exchange Commission process for approving shareholder proposals favors a left-wing bent in corporate policies, claims a watchdog, citing audits from 2018-2022.
Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year data
Pfizer expects its cancer drug Lorbrena to top $1 billion in annual sales by 2030 after most patients treated for a form of lung cancer had no disease progression after five years.
Pfizer shares sink after it resets 2024 COVID expectations
Pfizer, Inc. on Wednesday forecast 2024 sales that could be as much as $5 billion below Wall Street expectations, driving shares down 9% to a 10-year low.
Pfizer CEO slams presidents of elite colleges over ‘despicable’ antisemitism
Pfizer CEO Albert Bourla criticized the "despicable" testimony of three elite university presidents who were "hiding behind calls for 'context'" before deeming such rhetoric impermissible.
Pfizer scraps twice-daily weight loss pill danuglipron after study shows ‘high rates’ of adverse side effects
Pfizer is shelving development of a twice-daily version of its weight loss drug after a trial proved users reported high rates of adverse side effects.